The major lipoprotein risk factor for coronary heart disease in the United States today is low HDL cholesterol, usually accompanied by high triglycerides. The investigators intend to use our expertise in the molecular biology of the apolipoprotein genes and lipoprotein metabolism to create induced mutant mice and use them to study how apolipoprotein genes regulate HDL and triglyceride levels. The investigators will also carefully examine the implications of altered levels for atherosclerosis susceptibility. The current work will focus on the apo A-I, apo A-II and apo CIII genes. The investigators propose to use the apo A-I knockout mouse to study the effect of apo A-I on HDL metabolism and atherosclerosis susceptibility. In these studies the investigator will determine whether low HDL levels are an independent modifier of atherosclerosis and elucidate the mechanism. The investigator will examine possible overlapping functions of apo A-I and apo A-IV with regard to reverse cholesterol transport and atherosclerosis susceptibility. Finally, the investigator will study the apo A-I adrenal cell interaction to determine if an HDL/apo A-I receptor is involved and, if so, clone the receptor. The investigator will also generate and characterize apo A-II knockout mice and use these to define the functional role of apo A-II in vivo. The investigators will test whether apo A-II inhibits HL activity, inhibits remnant clearance, regulates FFA levels, and influences atherosclerosis susceptibility. The explorations of the apo CIII gene expression-hypertriglyceridemia relationship will continue. The investigators will use apo CIII knockout mice to test whether hypertriglyceridemia associated with insulin deficiency or resistance is mediated by apo CIII gene expression. The investigators will determine whether apo CIII promoter genetic variation controls insulin regulation of apo CIII gene expression and triglyceride levels in vivo. The investigators will examine the influence of the apo CIII gene Sstl 3'UTR polymorphism on apo CIII mRNA stability and determine possible interactions between the apo CIII promoter polymorphisms and the Sstl 3' UTR polymorphism.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL033714-16
Application #
6030527
Study Section
Metabolism Study Section (MET)
Program Officer
Laughlin, Maren R
Project Start
1984-07-01
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
16
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Rockefeller University
Department
Genetics
Type
Other Domestic Higher Education
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Liu, Simin; Song, Yiqing; Hu, Frank B et al. (2004) A prospective study of the APOA1 XmnI and APOC3 SstI polymorphisms in the APOA1/C3/A4 gene cluster and risk of incident myocardial infarction in men. Atherosclerosis 177:119-26
Liu, Simin; Ma, Jing; Ridker, Paul M et al. (2003) A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis 166:323-9
Trogan, Eugene; Choudhury, Robin P; Dansky, Hayes M et al. (2002) Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 99:2234-9
Han, Zhihua; Heath, Simon C; Shmulewitz, Dvora et al. (2002) Candidate genes involved in cardiovascular risk factors by a family-based association study on the island of Kosrae, Federated States of Micronesia. Am J Med Genet 110:234-42
Rong, J X; Li, J; Reis, E D et al. (2001) Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 104:2447-52
Tamminen, M; Mottino, G; Qiao, J H et al. (1999) Ultrastructure of early lipid accumulation in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19:847-53
Dansky, H M; Charlton, S A; Barlow, C B et al. (1999) Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium. J Clin Invest 104:31-9
Weng, W; Brandenburg, N A; Zhong, S et al. (1999) ApoA-II maintains HDL levels in part by inhibition of hepatic lipase. Studies In apoA-II and hepatic lipase double knockout mice. J Lipid Res 40:1064-70
Zaiou, M; Azrolan, N; Hayek, T et al. (1998) The full induction of human apoprotein A-I gene expression by the experimental nephrotic syndrome in transgenic mice depends on cis-acting elements in the proximal 256 base-pair promoter region and the trans-acting factor early growth response factor 1. J Clin Invest 101:1699-707
Weng, W; Breslow, J L (1996) Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc Natl Acad Sci U S A 93:14788-94

Showing the most recent 10 out of 73 publications